On Jun. 5, 2020, results were published in Science Immunology showed that Calquence (acalabrutinib), a Brutonﾒs tyrosine kinase (BTK) inhibitor, reduced markers of inflammation and improved clinical outcomes of patients with severe COVID-19 disease. The publication describes the effects of Calquence administration in patients with severe respiratory illness caused by the SARS-CoV-2 virus.